Original data · November 2026

How much can a compounded tirzepatide price tell you?

Of 384 providers in our recorded compounded tirzepatide roster, 20 have an advertised price that cannot be converted to a monthly total from the evidence held. This release shows the counts, the underlying rows and the dates behind them.

384providers in this snapshot
364with a monthly equivalent
20advertised-only quotes

Snapshot: November 3, 2026. Individual evidence dates vary. These are recorded observations, not a survey of every US provider or a claim that every price is current.

The gap between a quote and a comparable price

A low number alone does not establish what a plan costs. The amount charged, the time it covers and any required recurring fee are needed before prices can be put on the same basis. In this roster, 364 of 384 providers (94.8%) have a recorded monthly equivalent. Another 20 (5.2%) have an advertised figure without one.

Every provider in this snapshot has at least one recorded quote. This reflects the way our roster was assembled; it does not establish that every provider in the market publishes a price.

One selected price record per provider; these categories do not overlap.
Recorded price evidenceProvidersShare of roster
Monthly equivalent available36494.8%
Advertised figure only205.2%
No recorded quote00.0%

A monthly equivalent means the recorded fields support arithmetic. It does not establish the price of every dose, that all possible fees are known, or that someone completed a purchase. Our price-transparency analysis examines billing-cycle, dose and fee differences separately.

An analysis date is not a fresh price check

378 selected records (98.4%) carry evidence dates more than 30 days before this snapshot. An older observation may still be accurate, but its age should be visible to anyone using the data. We have not reset those dates to the report’s publication date.

Age of the selected price evidence on November 3, 2026
  • Within 30 days61.6%
  • 31–60 days20352.9%
  • 61–90 days17545.6%
  • More than 90 days00.0%
  • Date not recorded00.0%

Thirty days is a reporting bucket, not an expiry date or a Google ranking threshold. The age calculation applies to the selected record, not necessarily every alternative plan a provider offers.

Three prices, three things to check

Collective

$85.58 per calendar month

The plan in our Collective review lists $69.00 per month for medication in this snapshot. A required annual membership contributes $16.58 to the monthly equivalent. Spreading that fee over a year does not make it a monthly charge or a refundable commitment.

Luvo Health

$270.68 per calendar month

The plan in our Luvo Health review bills $249.00 every 28 days in this snapshot. A calendar month here is 30.4375 days, so the comparable amount exceeds one four-week payment. The first-cycle discount is excluded from this recurring figure.

NextMeds

$129.00 per calendar month

The one-month plan covered in our NextMeds review lists $129.00 per month in this snapshot. This record uses that plan, rather than the lower general homepage headline or an unverified longer commitment.

How to reproduce the findings

  1. Fix the roster and date. This version contains all 384 providers in this site’s compounded tirzepatide dataset on November 3, 2026, including records without a quote.
  2. Select one record per provider. Choose the lowest recorded computable monthly equivalent. If none exists, choose the lowest non-null advertised figure. Preserve source order on ties. This is an entry-plan comparison, not a maintenance-dose comparison.
  3. Keep missing values. Blank CSV cells and JSON nulls mean not recorded or not computable. A null fee does not mean no fee. Do not replace missing prices with zero.
  4. Use the same month. Where the recorded charge and interval support it, calculate charge ÷ covered days × 30.4375, then include recorded required recurring fees. One-time charges remain separate. See the full verification method.
  5. Count evidence age. Subtract the selected record’s evidence date from November 3, 2026. The age buckets and the three price-evidence categories each partition the complete roster.

This is a convenience sample of recorded provider observations. It is not a representative market survey, a treatment recommendation, or a comparison of clinical quality. Dose, duration, availability and terms differ. Public-page checks do not prove checkout completion. Compounded medications are not FDA-approved.

These files stay fixed when the live index changes. The current provider index and individual reviews may therefore contain newer observations. Corrections to this release will be documented rather than silently replaced.

Use the data

Cite this snapshot

Compounded Tirzepatide, price evidence snapshot, November 3, 2026. https://compoundedtirzepatide.org/research/price-evidence-november-2026

Reuse is governed by our data terms. Link to this report when citing its findings. CSV rows include the source-site URL and canonical report URL.

Snapshot fingerprint227816171eb21144a0bd727dae28a41f568b8b4a3ba5cf7e623fce61cac4c346